Dr. Shah Discusses P53-Mutated Mantle Cell Lymphoma

Bijal D. Shah, MD
Published: Tuesday, Oct 24, 2017



Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Shah states that his first choice for patients with p53-mutated MCL is lenalidomide (Revlimid).

Additionally, Shah says that the next big biomarker will focus on minimal residual disease, as it has been shown to predict for relapse down the line.
 


Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Shah states that his first choice for patients with p53-mutated MCL is lenalidomide (Revlimid).

Additionally, Shah says that the next big biomarker will focus on minimal residual disease, as it has been shown to predict for relapse down the line.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x